Is very low LDL-C harmful?
Faselis C, Imprialos K, Grassos H, Pittaras A, Kallistratos M, Manolis A
Current pharmaceutical design · 18 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Revisión sistemática (clasificado por nuestro filtro de IA)
- Estudiado en
- Personas
- Resultado principal
- Eventos clínicos como enfermedad o muerte
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2018-10-08 · Curr Pharm Des · vol. 24 · número 31 · págs. 3658–3664
- Editorial
- Bentham Science Publishers
- Citado
- 27 citas · más que el 91% de estudios similares · 3.1× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 0 trabajos
- Acceso
- De pago
- Áreas de investigación
- Lipoproteins and Cardiovascular Health · Cholesterol and Lipid Metabolism · Blood Pressure and Hypertension Studies
- Palabras clave
- very low LDL-C, LDL cholesterol, cardiovascular risk, lipid-lowering therapy, statins, ezetimibe, PCSK9 inhibitors, drug safety, hemorrhagic stroke, cancer risk, LDL-C target levels
- MeSH
- animals, humans, cardiovascular diseases, risk factors, homeostasis, cholesterol, ldl
6 autores
- Charles J. Faselis🇺🇸 · autor de correspondenciaGeorge Washington University; Washington DC VA Medical Center
- Konstantinos P. Imprialos🇬🇷Aristotle University of Thessaloniki
- Haris Grassos🇬🇷KAT General Hospital of Attica
- Andreas E. Pittaras
- Manolis S. Kallistratos
- Athanasios J. Manolis
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Low-density Lipoprotein Cholesterol (LDL-C) is a major Cardiovascular (CV) risk factor. Accumulating evidence supports a linear association between LDL-C levels and CV risk. However, the lower limit of LDL-C that might offer CV benefits without any safety concerns is still a topic of debate.
Objective
The purpose of this review is to present the safety of reducing LDL-C to low levels as it comes from major lipid-lowering drug studies, and to discuss data on several safety events that have been associated with low LDL-C levels.
Methods
A comprehensive literature search was performed to identify available data from clinical studies evaluating the association of low LDL-C with safety outcomes.
Results
Several large trials have evaluated the safety or reducing LDL-C to levels lower than 50 mg/dl or even lower than 25 mg/dl, more commonly with the use of a combination of statins with ezetimibe or proprotein convertase subtilisin kexin 9 inhibitors. In almost all trials, CV benefits were observed with LDL-C levels of 50 mg/dl or less compared with higher levels. In terms of safety, reduction of LDL-C to such levels was not associated with any significant adverse event. Of importance, cancer and hemorrhagic stroke incidences were not increased in patients attaining LDL-C lower than 40-50 mg/dl. Data regarding the impact of lowering LDL-C with neurocognitive disorders are contradictory; nevertheless, most studies stand in favor of neurocognitive safety with LDL-C reductions to low levels.
Conclusion
Achieving an LDL-C of 40-50 mg/dl seems to be safe, and importantly might offer CV beneficial effects. Data for attaining levels below 25 mg/dl is limited, however in favor of such reductions.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.